Spero Therapeutics Analyst Ratings
Spero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 400% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 08/01/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/20/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/10/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 09/26/2022 | 328.57% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 09/23/2022 | 471.43% | Evercore ISI Group | $2 → $8 | Upgrades | In-Line → Outperform |
| 08/15/2022 | 400% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
| 05/23/2022 | 614.29% | HC Wainwright & Co. | $37 → $10 | Maintains | Buy |
| 05/20/2022 | 42.86% | Berenberg | → $2 | Downgrades | Buy → Hold |
| 05/17/2022 | 257.14% | Cantor Fitzgerald | $27 → $5 | Maintains | Overweight |
| 05/04/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 05/04/2022 | 42.86% | Evercore ISI Group | $40 → $2 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 2542.86% | HC Wainwright & Co. | $43 → $37 | Maintains | Buy |
| 03/21/2022 | 2971.43% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/22/2021 | 2757.14% | HC Wainwright & Co. | $33 → $40 | Maintains | Buy |
| 12/16/2020 | 3257.14% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 11/23/2020 | 2257.14% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 09/29/2020 | 4900% | Evercore ISI Group | → $70 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1900% | HC Wainwright & Co. | $25 → $28 | Reiterates | → Buy |
| 03/17/2020 | 1400% | Stifel | $22 → $21 | Maintains | Buy |
| 11/05/2019 | 2400% | HC Wainwright & Co. | $28 → $35 | Maintains | Buy |
| 09/09/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 09/04/2019 | 1900% | HC Wainwright & Co. | → $28 | Assumes | → Buy |
| 10/16/2018 | 542.86% | B of A Securities | $19 → $9 | Downgrades | Neutral → Underperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 400% | HC Wainwright公司 | $6→$7 | 维护 | 买 |
| 08/01/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 07/20/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 04/10/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 09/26/2022 | 328.57% | HC Wainwright公司 | $7→$6 | 维护 | 买 |
| 09/23/2022 | 471.43% | Evercore ISI集团 | $2→$8 | 升级 | 线内→表现优异 |
| 2022年08月15日 | 400% | HC Wainwright公司 | $10→$7 | 维护 | 买 |
| 2022年05月23日 | 614.29% | HC Wainwright公司 | $37→$10 | 维护 | 买 |
| 05/20/2022 | 42.86% | 贝伦伯格 | →$2 | 评级下调 | 购买→Hold |
| 2022/05/17 | 257.14% | 康托·菲茨杰拉德 | $27→$5 | 维护 | 超重 |
| 05/04/2022 | - | 考恩公司 | 评级下调 | 跑赢→市场表现 | |
| 05/04/2022 | 42.86% | Evercore ISI集团 | $40→$2 | 评级下调 | 胜过→同线 |
| 04/18/2022 | 2542.86% | HC Wainwright公司 | $43→$37 | 维护 | 买 |
| 03/21/2022 | 2971.43% | HC Wainwright公司 | $40→$43 | 维护 | 买 |
| 10/01/2021 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 2021/01/22 | 2757.14% | HC Wainwright公司 | $33→$40 | 维护 | 买 |
| 12/16/2020 | 3257.14% | 贝伦伯格 | →$47 | 开始承保 | →购买 |
| 11/23/2020 | 2257.14% | HC Wainwright公司 | $28→$33 | 维护 | 买 |
| 09/29/2020 | 4900% | Evercore ISI集团 | →$70 | 开始承保 | →跑赢大盘 |
| 05/11/2020 | 1900% | HC Wainwright公司 | $25→$28 | 重申 | →购买 |
| 03/17/2020 | 1400% | Stifel | $22→$21 | 维护 | 买 |
| 2019年11月05日 | 2400% | HC Wainwright公司 | $28→$35 | 维护 | 买 |
| 2019年09月09日 | - | 詹尼·蒙哥马利·斯科特 | 开始承保 | →购买 | |
| 2019年09月04日 | 1900% | HC Wainwright公司 | →$28 | 假设 | →购买 |
| 2018年10月16日 | 542.86% | B of A证券 | $19→$9 | 评级下调 | 中性→表现不佳 |
What is the target price for Spero Therapeutics (SPRO)?
Spero治疗公司(SPRO)的目标价格是多少？
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 400.00% upside). 7 analyst firms have reported ratings in the last year.
2023年8月14日，HC Wainwright&Co.报道了Spero治疗公司(纳斯达克代码：SPRO)的最新目标价。这家分析公司将目标价定为7美元，预计SPRO将在12个月内升至(可能上涨400.00%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
Spero治疗公司(SPRO)的最新分析师评级是多少？
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics maintained their buy rating.
对斯佩罗治疗公司(纳斯达克代码：SPO)的最新分析师评级由HC Wainwright&Co.提供，斯佩罗治疗公司维持其买入评级。
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Spero治疗公司(SPRO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Spero治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Spero治疗公司的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右的某个时候提供。
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
分析师对Spero Treeutics(SPRO)的评级正确吗？
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a maintained with a price target of $6.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.40, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Spero治疗公司(SPRO)评级保持不变，目标价在6.00美元至7.00美元之间。Spero治疗公司(SPRO)目前的交易价格为1.40美元，超出了分析师的预测范围。